Kronos Bio, Inc. KRON
We take great care to ensure that the data presented and summarized in this overview for Kronos Bio, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding KRON
View all-
Vanguard Group Inc Valley Forge, PA1.92MShares$1.69 Million0.0% of portfolio
-
Partners Capital Investment Group, LLP Boston, MA1.45MShares$1.27 Million0.02% of portfolio
-
Alphabet Inc. Mountain View, CA1.44MShares$1.27 Million0.11% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.43MShares$1.25 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA1.35MShares$1.18 Million0.07% of portfolio
-
Wildcat Capital Management, LLC1.3MShares$1.14 Million0.62% of portfolio
-
Acadian Asset Management LLC Boston, MA1.23MShares$1.08 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.1MShares$970,0460.0% of portfolio
-
Black Rock Inc. New York, NY874KShares$769,2090.0% of portfolio
-
Siren, L.L.C. New York, NY843KShares$741,7990.04% of portfolio
Latest Institutional Activity in KRON
Top Purchases
Top Sells
About KRON
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Insider Transactions at KRON
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 20
2025
|
Deborah Knobelman President & Interim CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
139,422
-100.0%
|
$0
$0.57 P/Share
|
|
Jun 20
2025
|
Joshua A Kazam |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
94,481
-100.0%
|
$0
$0.57 P/Share
|
|
Jun 20
2025
|
Taiyin Yang |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
11,333
-100.0%
|
$0
$0.57 P/Share
|
|
Jun 20
2025
|
David M Tanen |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
550,355
-100.0%
|
$0
$0.57 P/Share
|
|
Jun 20
2025
|
David M Tanen |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
363,428
-100.0%
|
$0
$0.57 P/Share
|
|
Jun 20
2025
|
Elena Ridloff |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
25,296
-100.0%
|
$0
$0.57 P/Share
|
|
Jun 20
2025
|
Norbert W Bischofberger |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
11,857,138
-100.0%
|
$0
$0.57 P/Share
|
|
Jun 20
2025
|
Arie Belldegrun |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
3,444,889
-100.0%
|
$0
$0.57 P/Share
|
|
Jun 05
2025
|
Deborah Knobelman President & Interim CEO |
SELL
Open market or private sale
|
Direct |
24,838
-15.12%
|
$0
$0.87 P/Share
|
|
Jun 28
2024
|
Norbert W Bischofberger |
BUY
Open market or private purchase
|
Indirect |
204,670
+1.86%
|
$204,670
$1.25 P/Share
|
|
Jun 27
2024
|
Norbert W Bischofberger |
BUY
Open market or private purchase
|
Indirect |
410,848
+3.73%
|
$410,848
$1.17 P/Share
|
|
Jun 25
2024
|
Elena Ridloff |
BUY
Grant, award, or other acquisition
|
Direct |
11,333
+30.94%
|
-
|
|
Jun 12
2024
|
Norbert W Bischofberger |
BUY
Open market or private purchase
|
Indirect |
881,913
+10.68%
|
$881,913
$1.24 P/Share
|
|
Jun 11
2024
|
Norbert W Bischofberger |
BUY
Open market or private purchase
|
Indirect |
744,308
+10.28%
|
$744,308
$1.09 P/Share
|
|
Jun 10
2024
|
Norbert W Bischofberger |
BUY
Open market or private purchase
|
Indirect |
1,378,901
+19.34%
|
$0
$0.88 P/Share
|
|
Jun 03
2024
|
Deborah Knobelman President & Interim CEO |
BUY
Grant, award, or other acquisition
|
Direct |
164,260
+50.0%
|
-
|
|
Feb 21
2024
|
Elizabeth A Olek SR VP, CLINICAL SCIENCE |
SELL
Open market or private sale
|
Direct |
7,368
-3.67%
|
$7,368
$1.05 P/Share
|
|
Feb 21
2024
|
Allison Frisbee Chief Administrative Officer |
SELL
Open market or private sale
|
Direct |
12,105
-5.59%
|
$12,105
$1.05 P/Share
|
|
Feb 21
2024
|
Charles Y Lin Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,036
-4.88%
|
$12,036
$1.05 P/Share
|
|
Feb 15
2024
|
Norbert W Bischofberger |
BUY
Grant, award, or other acquisition
|
Direct |
270,339
+8.77%
|
-
|
Last 12 Months Summary
| Disposition due to a tender of shares in a change of control transaction | 16.5M shares |
|---|---|
| Open market or private sale | 24.8K shares |